The use of multiple maternal serum biochemical markers in screening for Down syndrome is gaining worldwide acceptance. We sought tostudy the impact of the potential instability of intact human chorionic gonadotropin (hCG) on free -hCG subunit, a marker that has recently been used successfully in such screening. We found that, in practice, any changes in free -hCG due to the instability of intact hCG do not inhibitthe effectiveness of free -hCG as a marker for Down syndrome. This was proven by controlled laboratory experiments at various stress temperatures, freeze-thaw studies, and analysis of a large set of screening data with particular reference to time in transit for indMdual samples. Data from controlled dissociation studies demonstrate that any apparent increase in free -hCG due to the instability of intact hCG cannot be attributed simply to the dissociation of intact hCG. Finally,for large-scale mass populationscreening in areas of the world where transport delays, safety concerns, and high temperatures preclude the shipment of liquidwhole blood, dried whole-blood spots on filter paper provide a suitable delivery system with many advantages. Stability testing has its roots in the pharmaceutical industry, where various techniques, including thermal degradation studies, have been used since the early 1950s to determine the shelf life of pharmaceutical products (10) and more recently have been implemented in the production of biological standards (9) and the manufacture of quality-control material (11).
The use of multiple maternal serum biochemical markers in screening for Down syndrome is gaining worldwide acceptance. We sought tostudy the impact of the potential instability of intact human chorionic gonadotropin (hCG) on free -hCG subunit, a marker that has recently been used successfully in such screening. We found that, in practice, any changes in free -hCG due to the instability of intact hCG do not inhibitthe effectiveness of free -hCG as a marker for Down syndrome. This was proven by controlled laboratory experiments at various stress temperatures, freeze-thaw studies, and analysis of a large set of screening data with particular reference to time in transit for indMdual samples. Data from controlled dissociation studies demonstrate that any apparent increase in free -hCG due to the instability of intact hCG cannot be attributed simply to the dissociation of intact hCG. Finally,for large-scale mass populationscreening in areas of the world where transport delays, safety concerns, and high temperatures preclude the shipment of liquidwhole blood, dried whole-blood spots on filter paper provide a suitable delivery system with many advantages. We have recently established, in both independent (1) (2) (3) and joint studies (4) , that the free a-subunit of chorionic gonadotropin (hCG) is the marker of choice for detecting chromosomal trisomies in early gestation, even during the first trimester (5). It has been suggested, based on anecdotal evidence (6) , that the concentrations of free 13-hCG increase as a result of improper sample storage, transport of samples at ambient temperature, and leaving samples at ambient temperature for 30 mm or more. This is allegedly due to the instability of intact hCG, resulting in release of the -hCG subunit. Gau et al. (7) and Bidart et al. (8) have described increased concentrations of free 13-and free a-hCG in serum samples that had been heated to deplete the serum complement components. However, this involved heating serum to 56#{176}C for 30 mm-clearly not a realistic environment for Down syndrome screening samples.
Most biological materials consist of large and complex molecules and it is characteristic of such materials that were raised against sterically remote epitopes on the 3-hCG molecule that are obscured when the p-hCG is in combination with the a-subunit. The monoclonal capture antibody used in this assay is named FBT11. The analytical performance of this assay has been previously described (2). The assay was calibrated against the First International Reference Preparation (75/551) for free /3-hCG.
We also measured free f3-hCG with the microtiter plate ELISA described by Macri et al. (1, 17) . The microtiter plate imxnunoassay was performed in duplicate, and absorbance measurements were made with an SLT plate reader [Tecan (UK) Ltd., Berkshire, UK]. The CV of assays of duplicates of each patient's sample was <5%.
The specificity of both the CIS assay and the ELISA has been previously described (17) and shown to be For filter-paper spot studies, we punched 5-mm-diameter spots from the collection cards and analyzed them in a modified form of the ELISA, using whole-blood spot calibrators.
The between-assay precision (CV) of this assay at 11.2 lUlL was 2.9% and at 17.8 lU/L was 4.2%.
Measurement of Free a-Subunit
Free a-hCG was measured with a solid-phase two-site immunoradiometric assay (Biocode Free Alpha Subunit IRMA, Metachem Diagnostics Ltd., Northampton, UK).
The assay was calibrated against the First International Reference Preparation (75/569) for a-hCG. The quoted cross-reactivity with intact hCG was <0.1%, and free J3-hCGwas undetectable.
All assays were performed in duplicate according to the manufacturer's conditions. The bound radioactivity was counted with an NE 1600 multihead gamma counter (NE Technology Ltd., Reading, UK); the counts were processed by using the WHO mass action curvefitting routine (19) . Counting times were adjusted to accumulate 10000 counts at a concentration of 2 lU/L for free (3-hCG and 0.5 lU/L for free a-hCG.
Protocols
Accelerated degradation study. The degradation rate constant for free /3-hCG was determined at 60#{176}C (333 K), 37 #{176}C (310 K), 20#{176}C (293 K), and 4 #{176}C (277 K). For each temperature to be analyzed, 10 patients'samples were divided into 500-tL aliquots and placed in water baths or a refrigerator at the respective experimental temperature.
For the 60#{176}C study, aliquots of the samples were removed to and placed at 4#{176}C at 5-min intervals for 1 h. All aliquots were then analyzed within the same assay batch.
For the 37#{176}C study, aliquots were removed to 4#{176}C at 24-h intervals for 1 week. All aliquots were then analyzed within the same assay batch. In a separate experiment we repeated the 37#{176}C study, using samples with added sodium aside, 1 gIL.
For the 20#{176}C study, aliquots were removed at daily intervals for the first week and at weekly intervals for a further 4 weeks. Aliquots taken over the first week were stored at 4#{176}C and analyzed in the same batch. Each series of subsequent weekly aliquots were analyzed together at the end of each week. The between-assay precision over the assay period was monitored with our internal quality-control procedures, which demonstrated a between-assay CV for free f3-hCG of 6.3% at 1.09 lU/L, 4.9% at 11.73 lU/L, 3.8% at 21.09 lU/L, and 4.4% at 40.89 IU/L.
For the 4#{176}C study, aliquots were removed at weekly intervals for 4 weeks. Each series of weekly aliquots were analyzed together, along with those from the 20#{176}C study.
Liquid whole-blood stability study. To simulate delays in sample separation, such as might occur in postal transport of specimens to the receiving laboratory, we divided whole blood from 10 patients into two portions. The first portion was allowed to clot and the serum was left on the clot at 22#{176}C. Aliquots were removed from each whole-blood sample after gentle inversion, the aliquots were centrifuged, and the serum aliquot was stored at 4#{176}C. This cycle was repeated at daily intervals for 8 days. For the second portion, the serum was separated from the clot and left at 22#{176}C. Aliquots were removed from each sample at daily intervals (for 8 days) and stored at 4#{176}C. AU serum aliquots were analyzed within the same assay batch.
Dried filter-paper blood-spot stability study. To assess the stability of whole blood transported as dried wholeblood spots on filter paper, we spotted blood from five The liquid whole blood from each patient was aliquoted into four lots and then stored at the respective storage temperatures (4#{176}C, 25#{176}C, and 37#{176}C) along with the respective dried filter-paper blood spot. After 9 days at the storage temperature, the liquid whole-blood samples were measured in one batch in the conventional ELISA procedure and the dried blood spots were analyzed in the modified blood-spot ELISA procedure.
Freeze/thaw study. To assess the impact of repeated freezing and thawing of samples on their free p-hCG concentration, we subjected 10 patients' samples to a series of freeze/thaw cycles. Samples were allowed to thaw at room temperature, an aliquot was removed to 4#{176}C, and the samples were returned to the freezer (-20 #{176}C) until they had frozen again. This cycle was repeated 25 times over the next 48 h and the aliquots were analyzed together within the same assay batch. 
Results
To calculate the activation energy, one must first calculate the degradation rate constant at each "stress" temperature, which can be obtained by plotting the relative changes of analyte concentration with time. Figure 1 shows such a plot for the 20#{176}C study. The slope of the regression line is the degradation rate constant. For each of the "stress" temperatures-4, 20, 37, and 60#{176}C-the degradation rate constants were 0.000023, 0.0016, 0.0077, and 1.105, respectively. Figure 2 shows the Arrhenius plot obtained by plotting the various degradation rate constants against the reciprocal of the absolute temperature.
The slope of the regression line is the activation energy (Ea). The stability of any analyte is commonly held to be the time required to initiate a 10% change from the original analyte concentration (11). The stability of free $-hCG is therefore calculated from the relationship:
0.105/K1
where K1 is the reactionrate constant at the stability temperature, derived from the regression equation of the Arrhenius plot. Table 1 Table 2 shows data for a series of five samples for which, after accelerated degradation at 37 and 60#{176}C, the relative change in free a-hCG and free $-hCG is expressed in molar terms. Molarity was calculated from the established primary structures (20): 15 kDa for free a-subunit and 23 kDa for free p-subunit. At both temperatures the mean free a/free molar ratio increase was 0.515: i.e., for every 1-mol increase in free a-, there was a 2-mol increase in free /3-hCG.
The freeze/thaw study showed a 2.5% increase in free p-hCG after 10 freeze/thaw cycles, with an 11% increase after 25 freeze/thaw cycles. Therefore, prior thawing and refreezing of stored Down syndrome samples is highly unlikely to influence free p-hCG concentrations ., a 2.8% change in 24.36 h) .
In the study of the impact of a 10% artifactual increase in free p-hCG in samples from 685 consecutive screened patients, we determined that an increase of only 1% (from 5.1% to 6.1%) in the initial positive rate would have been observed.
Study of the stability of free j3-hCG in dried wholeblood filter-paper spots compared with the same samples stored as liquid whole blood showed that storage for 9 days at 4#{176}C did not affect the stability in either material. At 25#{176}C, the liquid whole blood showed a twofold increase in free p-hCG over the 9 days, but that in the blood spot showed no increase. Even after storage at 37#{176}C for 9 days, the dried blood-spot free p-hCG was stifi stable, whereas the liquid whole blood showed a 13-fold increase in free p-hCG concentration.
DIscussion
Our study of the stability of free p-hCG in serum indicates that, contrary to anecdotal citation (6), serum concentrations of free p-hCG do not increase in samples left at ambient temperature for 30 mm. Our data at high temperatures are consistent with the published data of Bidart et al. (8) , who also demonstrated at 56#{176}C increases in both free a-and free f3-hCG concentrations. By using assays that recognize both nicked and nonnicked free p-hCG, we have alsotaken into account any altered stability of either of these forms.
We attempted to clarif' the source of the increase in free /3-hCG at high temperatures by also monitoring free a-hCG. If the increased free p-hCG were occurring as a result of dissociation of intact hCG, then by observing both free a-and free -hCG in samples exposed to spot collection of whole blood will become the method of choice: in this medium, free p-hCG is stable at 37#{176}C for >9 days. a-Fetoprotein, another marker used in conjunction with free p-hCG, was also stable after 9 days at 37#{176}C (data not shown). Filterpaper spot collection procedures also provide other advantages, particularly patient/clinician convenience, low cost, and, more importantly, reduced potential for transmission of disease in the collection, transportation, and laboratory handling of biological fluids.
By using standard sample collection and transportation protocols that can avoid artifactual changes in all analytes, the superior clinical utffity of the free p-hCG marker in screening for Down syndrome can be fully realized.
